Yoshida Sayaka, Nakamura Naoya, Sasaki Yoshikazu, Yoshida Sachiko, Yasuda Mitsuhiko, Sagara Hiroya, Ohtake Tohru, Takenoshita Seiichi, Abe Masafumi
Second Department of Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Mod Pathol. 2005 Mar;18(3):398-405. doi: 10.1038/modpathol.3800266.
Primary breast diffuse large B-cell lymphoma has a poor prognosis relative to other extranodal diffuse large B-cell lymphoma. Recently, diffuse large B-cell lymphoma has been subclassified as germinal center B-cell-like and nongerminal center B-cell types using tissue microarrays. The 5-year overall survival rate of the germinal center B-cell group is better than that of the nongerminal center B-cell group. To elucidate the reason for which primary breast diffuse large B-cell lymphoma has a poor clinical outcome, we investigated 15 patients with primary breast diffuse large B-cell lymphoma (stage IE; 13 cases, stage IIE; two cases) by immunohistochemistry using various markers including CD10, Bcl-6, MUM1 and MIB-1 and by molecular analysis of the immunoglobulin heavy chain gene variable region. Immunohistochemistry showed 0/15 (positive cases/examined cases) for CD10, 5/15 for Bcl-6, 15/15 for MUM1, 10/15 for Bcl-2, 2/15 for CD5 and 4/15 for CD40. The expression pattern of CD10(-) MUM1(+) in primary breast diffuse large B-cell lymphoma corresponded to the nongerminal center B-cell group. Moreover, the MIB-1 index was distributed from 60 to 95% with a mean of 79%, indicating a high proliferation of the lymphoma cells. The immunoglobulin heavy chain gene variable region of primary breast diffuse large B-cell lymphoma had a mutation frequency of 1-10% (seven cases) and 0-1 additional mutations in ongoing mutation analysis (five cases). Primary breast diffuse large B-cell lymphoma had characteristics of the nongerminal center B-cell group. In conclusion, primary breast diffuse large B-cell lymphoma has a nongerminal center B-cell phenotype and has a high MIB-1 index. These features might therefore be associated with poor prognosis.
原发性乳腺弥漫性大B细胞淋巴瘤相对于其他结外弥漫性大B细胞淋巴瘤预后较差。最近,利用组织芯片已将弥漫性大B细胞淋巴瘤分为生发中心B细胞样和非生发中心B细胞型。生发中心B细胞组的5年总生存率优于非生发中心B细胞组。为阐明原发性乳腺弥漫性大B细胞淋巴瘤临床预后较差的原因,我们采用免疫组织化学方法,使用包括CD10、Bcl-6、MUM1和MIB-1等多种标志物,对15例原发性乳腺弥漫性大B细胞淋巴瘤患者(IE期;13例,IIE期;2例)进行了研究,并对免疫球蛋白重链基因可变区进行了分子分析。免疫组织化学显示,CD10为0/15(阳性病例/检查病例),Bcl-6为5/15,MUM1为15/15;Bcl-2为10/15,CD5为2/15,CD40为4/15。原发性乳腺弥漫性大B细胞淋巴瘤中CD10(-)MUM1(+) 的表达模式与非生发中心B细胞组一致。此外,MIB-1指数分布在60%至95%之间,平均为79%,表明淋巴瘤细胞增殖活跃。原发性乳腺弥漫性大B细胞淋巴瘤免疫球蛋白重链基因可变区的突变频率在1%至10%之间(7例),在进行中的突变分析中有0至1个额外突变(5例)。原发性乳腺弥漫性大B细胞淋巴瘤具有非生发中心B细胞组的特征。总之,原发性乳腺弥漫性大B细胞淋巴瘤具有非生发中心B细胞表型且MIB-1指数较高。因此,这些特征可能与预后较差有关。